Skip to main content

Advertisement

Table 4 Amino acid mutations in the HCV NS5B protein in DAA-naïve patients infected with HCV genotypes 1a (n = 32) or 1b (n = 30)

From: Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients

  NS5B mutations in DAA-naïve patients
DAAs Genotype 1a Fold change in EC50 Genotype 1b Fold change in EC50 References
  S96Tγ   S96T   
  N142T   N142T   
Sofosbuvir + Mericitabine L159F   L159F (7/30, 23.3%) Xβ [32]
  C223H/Y   C223H/Y   
  S282T   S282T   
  L320F   L320F   
PSI-352938 V321I (1/32, 3.1%) α 2.0 V321I (1/30, 3.3%) 2.0 [17, 33]
Tegobuvir + HCV796 C316Y/N/F/S   C316N (11/30, 36.6%) 3.0-5.2 [17, 34]
  V362A   V362A   
  S365A/T   S365A/T   
  M414T   M414T   
  L419M/S   L419M/S   
  A421V   A421V   
  R422K   R422K   
  M423I/V/T   M423I/V/T   
Filibuvir M426L (1/32, 3.1%) 0.8 M426L (2/30, 6.6%) 0.8 [21]
  C445F   C445F   
Tegobuvir Y448H (1/32, 3.1%) 36.0 Y448H   [34]
Tegobuvir Y452H (1/32, 3.1%) 6.9 Y452H (1/30, 3.3%) 6.9 [34]
Tegobuvir R465G   R465G (1/30, 3.3%) 1.1 [34]
  I482L/T   I482L/T   
  A486V   A486V   
  V494A   V494A   
  P495A/L/S/T   P495A/L/S/T   
  P496A/S   P496A/S   
JTK-109 + Deleobuvir A499T   V499A (4/30, 13.3%) 3.0 [17, 35]
  G554D   G554D   
  S556G/D/N   S556G/D/N   
  D559G/N   D559G/N   
  1. αAmino acid changes conferring resistance to NS5B inhibitors are reported in italics. The number and % of patients with mutated strains is reported in brackets. βResistance levels are reported only when associated with L320F. GeneBank NS5B reference sequence accession number for HCV genotype 1a is AF009606, and for genotype 1b, AY045702.